期刊文献+

TS基因表达与培美曲塞治疗老年晚期肺腺癌疗效关系的研究 被引量:8

The relationship between expression of thymidylate synthase and therapeutic effect of pemetrexed on senile advanced pulmonary adenocarcinoma patients
下载PDF
导出
摘要 目的探讨老年晚期肺腺癌患者胸苷酸合成酶(TS)基因与培美曲塞疗效的关系。方法收集37例老年晚期肺腺癌患者,随机分为培美曲塞联合卡铂方案组和紫杉醇联合卡铂方案组;RT-PCR检测肿瘤组织中TS mRNA的表达,Western blotting检测TS蛋白的表达。结果两组疾病控制率差异无统计学意义。TS mRNA和蛋白的表达与年龄、性别及分期无关。培美曲塞联合卡铂组中获疾病控制者(CR+PR+SD)的TS mRNA和蛋白表达量为5.08±2.30和4.46±2.22,进展者(PD)为13.66±3.84和12.6±3.92,差异均有统计学意义(P<0.05)。紫杉醇联合卡铂方案组中获疾病控制者与进展者的TS mRNA和蛋白表达差异均无统计学意义(P>0.05)。结论肺腺癌患者肿瘤组织中TS基因的表达与患者对培美曲塞的敏感性相关,TS基因高表达提示对培美曲塞敏感性降低。 Objective To investigate the expression of thymidylate synthase(TS) in senile patients with advanced pulmonary adenocarcinoma and its relationship with the therapeutic effect of pemetrexed.Methods A total of 37 senile advanced pulmonary adenocarcinoma patients were randomized into pemetrexed plus carboplatin group and paclitaxel plus carboplatin group.RT-PCR was used to examine TS mRNA,and Western blotting was used to analyze TS protein.Results There was no significance in the disease control rate of the two groups.The expression of TS mRNA and protein was not related to age,gender and clinical stage.In pemetrexed plus carboplatin group,the TS mRNA of response(CR+PR+SD) and no response group(PD) was 5.08±2.30 and 13.66±3.84(P0.05).The expression level of TS protein of response and no response group was 4.46±2.22 and 12.96±3.92(P0.05).However,there was no significant difference between these patients in paclitaxel plus carboplatin group neither in TS mRNA nor in TS protein(P0.05).Conclusion The expression of TS gene in pulmonary adenocarcinoma biopsy is related to the sensitivity to pemetrexed.Patients with high expression of TS gene will have poor response to pemetrexed.
出处 《临床肿瘤学杂志》 CAS 2012年第4期317-320,共4页 Chinese Clinical Oncology
基金 江苏省卫生厅基金资助项目(H201023) 江苏省自然科学基金资助项目(BK2011842)
关键词 胸苷酸合成酶 肺腺癌 化学治疗 培美曲塞 Thymidylate synthase Pulmonary adenocarcinoma Chemotherapy Pemetrexed
  • 相关文献

参考文献9

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55 (2) :74 -108.
  • 2Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med, 2002, 346(2) : 92-98.
  • 3Gangjee A, Jain HD, Kurup S. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infec- tion agents: Part Ⅱ [J]. Anticancer Agents Med Chem, 2008, 8 (2) : 205-231.
  • 40zasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer[J]. Cancer Sci, 2010, 101 ( 1 ) : 161-166.
  • 5Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer[J]. Br J Cancer, 2011, 104 (10) : 1594-601.
  • 6Joerger M, Omlin A, Cemy T, et al. The role of pemetrexed inadvanced non small-cell lung cancer: special focus on pharmacology and mechanism of action[J]. Curr Drug Targets, 2010, 11 (1) : 37-47.
  • 7Sun JM, Han J, Ahn JS, Park K, et al. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy[J]. J Thorac Oncol, 2011, 6 (8) :1392-1399.
  • 8Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in nonsmall cell lung carcinoma: the association with treatment efficacy of pemetrexed [ J ]. Lung Cancer, 2011, 74 ( 1 ) : 132-138.
  • 9Uramoto H, Onitsuka T, Shimokawa H, et al. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed[J]. Anticaneer Res, 2010, 30(10):4309-4315.

同被引文献87

  • 1余敏,姜宏宁.小剂量多西他赛单药维持治疗老年晚期非小细胞肺癌的临床观察[J].实用老年医学,2013,27(1):66-69. 被引量:6
  • 2郑积华,张为民,谢波,林金容,周娟,徐志勇.多西他赛或培美曲塞一线治疗老年晚期肺腺癌的疗效及预后因素分析[J].肿瘤防治研究,2014,41(6):641-644. 被引量:8
  • 3Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics2002[J]. CA Cancer J Clin,2005, 55(2) :74 - 108.
  • 4Seagliotti GV, Parikh P, von Pawel J et al. Phase 111 study com- paring cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small- cell lung cancer[ J]. J Clin Oncol, 2008, 26(2) :3543 - 3551.
  • 5Pirker R, Periera JR_, Szczesna A, et al. Cetuximab plus chemo- therapy in patients with advanced non-small-cell lung cancer (FLEX) : an open label randomised phase IU trial[ J]. Lancet, 2009, 373 (9674) : 1525 - 1531.
  • 6Grnberg BH, Bremnes RM, Flatten O, et al. Phase [1I study by the Norwegian lung cancer study group: pemetrexed plus carbo- platin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer J ]. J Clin Oncol, 2009, 27(19) :3217 -3224.
  • 7Shih C, Chen VJ, Gossett l-S, et al. LY231514, a pyrrolo[2,3- d] pyrimidine-based antifolate that inhibits multiple folate-requi- ring enzymes[J]. Cancer Res, 1997, 57 (6) :1116 -1123.
  • 8Sehultz RM, Patel VF, Worzalla JF, et al. Role of thymidylate synthase in the antitumor activity of the muhitargeted antifolate, LY231514[J]. Antieaneer Res,1999, 19(1A) :437 -443.
  • 9Smith PG, Marshman E, Newell DR, et al. Dipyridamole poten- tiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport[ J]. Br J Cancer,2000,82(4) :924 -930.
  • 10Cohen MH, Johnson JR, Wang YC, et al. FDA drug approval sum- mary: Pemetrexed for injection (Alimta) for the treatment of non- small cell lung cancerOUS. Oncololst,2005,10(6) :363 -368.

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部